Filtered By:
Condition: Pregnancy
Vaccination: Cancer Vaccines
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 144 results found since Jan 2013.
Human Papillomavirus Inpatient Postpartum Vaccination: Clinical Guideline Implementation
CONCLUSION: Non-Hispanic White, Spanish-speaking, and married patients were disproportionally undervaccinated in our baseline population, but about one quarter of vaccine-eligible patients received 9vHPV vaccination postpartum. Inpatient postpartum 9vHPV vaccination may help narrow disparities in vaccination.PMID:37348091 | DOI:10.1097/AOG.0000000000005220
Source: Obstetrics and Gynecology - June 22, 2023 Category: OBGYN Authors: Ellen C Murphy Stephanie Alimena Andrea Pelletier Nicole Sczekan Nicole A Smith Julianna Schantz-Dunn Khady Diouf Sarah Feldman Source Type: research
Here, There, and Everywhere: Myeloid-Derived Suppressor Cells in Immunology
J Immunol. 2023 May 1;210(9):1183-1197. doi: 10.4049/jimmunol.2200914.ABSTRACTMyeloid-derived suppressor cells (MDSCs) were initially identified in humans and mice with cancer where they profoundly suppress T cell- and NK cell-mediated antitumor immunity. Inflammation is a central feature of many pathologies and normal physiological conditions and is the dominant driving force for the accumulation and function of MDSCs. Therefore, MDSCs are present in conditions where inflammation is present. Although MDSCs are detrimental in cancer and conditions where cellular immunity is desirable, they are beneficial in settings where ...
Source: Journal of Immunology - April 17, 2023 Category: Allergy & Immunology Authors: Suzanne Ostrand-Rosenberg Tracey J Lamb Graham Pawelec Source Type: research
Pregnancy-associated gynecological cancer in New South Wales, Australia 1994-2013: A population-based historical cohort study
CONCLUSIONS: The incidence of PAGC has not increased over time perhaps reflecting, in part, the effectiveness of cervical screening and early impacts of human papillomavirus vaccination programs in Australia. The higher rate of preterm birth among the gestational PAGC group is associated with adverse outcomes in babies born to these women.PMID:36915236 | DOI:10.1111/aogs.14530
Source: Cancer Control - March 14, 2023 Category: Cancer & Oncology Authors: Penelope Fotheringham Nadom Safi Zhouyang Li Antoinette Anazodo Marc Remond Andrew Hayen David Currow David Roder Nada Hamad Michael Nicholl Adrienne Gordon Jane Frawley Elizabeth A Sullivan Source Type: research
Attitudes toward COVID-19 vaccination during the state of emergency in Osaka, Japan
CONCLUSIONS: Most respondents expressed favorable attitudes toward COVID-19 vaccination while hesitancy was disproportionately high in certain populations. Efforts are needed to ensure accessible vaccine information resources and healthcare services.PMID:36584068 | PMC:PMC9803118 | DOI:10.1371/journal.pone.0279481
Source: Cancer Control - December 30, 2022 Category: Cancer & Oncology Authors: Satomi Odani Shihoko Koyama Yuichi Katsumi Isao Miyashiro Source Type: research
End of year message from Cochrane ' s CEO, Catherine Spencer
Dear Cochrane Colleagues, Members and Supporters, Thank you to everyone across our community for your dedication and commitment to Cochrane during 2022. The last few years have at times felt tumultuous, both due to Covid and world events, but also because of the changes we are making to ensure that Cochrane is fit for a future that meets our vision of aworld of better health for all people, where decisions about health and care are informed by high-quality evidence. We are well on our way to creating an evolved impact-driven organisation to support evidence-based health and social care. With your help we are building on ...
Source: Cochrane News and Events - December 20, 2022 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Spontaneous preterm birth risk among HPV vaccinated and unvaccinated women: a nationwide retrospective cohort study of over 240 000 singleton births
CONCLUSIONS: In this large, population-based cohort, we found reduced odds of spontaneous preterm birth among women HPV vaccinated at an early age compared to those unvaccinated. It seems conceivable that HPV vaccination may not only reduce the incidence of cervical cancer and severe precursors, but also the risk of preterm birth related to HPV infection.PMID:36424904 | DOI:10.1111/1471-0528.17349
Source: BJOG : An International Journal of Obstetrics and Gynaecology - November 25, 2022 Category: OBGYN Authors: E McClymont M T Faber F Belmonte S K Kjaer Source Type: research
SOGC Guideline Retirement Notice No. 3
J Obstet Gynaecol Can. 2022 Nov;44(11):1226-1236. doi: 10.1016/j.jogc.2022.09.005.ABSTRACTThese documents have been archived because they contain outdated information. They should not be consulted for clinical use, but for historical research only. Please visit the journal website for the most recent guidelines. Prenatal Screening for Fetal Aneuploidy [J Obstet Gynaecol Can 29 (2007) 146-161] AUTHORS Anne Summers, MD, North York, ON Sylvie Langlois, MD, Vancouver, BC Phil Wyatt, MD, PhD, Toronto, ON R. Douglas Wilson, MD, Philadelphia, PA A Report on Best Practices for Returning Birth to Rural and Remote Aboriginal Communi...
Source: Rural Remote Health - November 21, 2022 Category: Rural Health Source Type: research
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
A subtractive proteomics and immunoinformatics approach towards designing a potential multi-epitope vaccine against pathogenic Listeriamonocytogenes
Microb Pathog. 2022 Sep 20:105782. doi: 10.1016/j.micpath.2022.105782. Online ahead of print.ABSTRACTListeria monocytogenes is the causative agent of listeriosis, which is dangerous for pregnant women, the elderly or individuals with a weakened immune system. Individuals with leukaemia, cancer, HIV/AIDS, kidney transplant and steroid therapy suffer from immunological damage are menaced. World Health Organization (WHO) reports that human listeriosis has a high mortality rate of 20-30% every year. To date, no vaccine is available to treat listeriosis. Thereby, it is high time to design novel vaccines against L. monocytogenes...
Source: Cancer Control - September 23, 2022 Category: Cancer & Oncology Authors: Shakilur Rahman Amit Kumar Das Source Type: research
